VRDN - Viridian Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$36.88
DETAILS
HIGH:
$45.00
LOW:
$26.00
MEDIAN:
$38.50
CONSENSUS:
$36.88
UPSIDE:
92.38%
About Viridian Therapeutics, Inc. (https://www.viridiantherapeutics.com)
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Stephen F. Mahoney | Chief Executive Officer, President & Director | 1971 | $1,336,438 USD |
| Thomas W. Beetham | Chief Operating Officer | 1970 | $972,976 USD |
| Radhika Tripuraneni | Chief Medical Officer | 1980 | $840,686 USD |
| Jennifer Tousignant | Chief Legal Officer & Corporate Secretary | 1973 | $819,951 USD |
| Seth Harmon | Chief Financial Officer | 1981 | $785,651 USD |
| Eric N. Olson | Co-Founder & Chairman of Scientific Advisory Board | – | – |
| Marvin H. Caruthers | Co-Founder & Scientific Advisory Board Member | 1940 | – |
| Melissa Manno | Chief Human Resources Officer | – | – |
| Michael R. Bristow | Co-Founder & Member of the Scientific Advisory Board | 1945 | – |
| Vahe Bedian | Co-Founder & Scientific Advisor | – | – |